Status:
COMPLETED
The Effect of Gland Expression on the Regeneration of Meibomian Gland
Lead Sponsor:
Chulalongkorn University
Collaborating Sponsors:
King Chulalongkorn Memorial Hospital
Conditions:
Meibomian Gland Dysfunction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to compare the percentage of meibomian gland (MG) dropout in patients who are treated with additional meibomian gland expression (MGX) and in patients who are not. T...
Detailed Description
1. Study design: an assessor-blinded, randomized, controlled trial 2. Target population: MGD patients having mild to moderate MG dropout from Out-clinic at King Chulalongkorn Memorial Hospital (KCMH)....
Eligibility Criteria
Inclusion
- Diagnosis of obstructive MGD
- Visible Meibomian gland dropout of upper and lower eyelid from grade 1 to grade 2 (Arita's meiboscale)
- If both eyes meet above criteria, only right eye is chosen
Exclusion
- Diagnosis with secondary MGD
- Having any eyedrop other than eye lubricant within the last 3 months
- Any kind of eyelid treatment related to MGD within the last 6 months
- History of ocular trauma, ocular surface surgery or eyelid surgery
- History of intraocular surgery less than 6 months
- Eyelid botulinum toxin injection within the last 6 months
- Ocular diseases other than dry eye
- Pregnant or breast-feeding
- Wearing contact lens
- Using any hormones therapy, anti-inflammatory drugs, tetracycline and macrolides
- Refuse to participate in the study
Key Trial Info
Start Date :
October 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 6 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06163105
Start Date
October 3 2024
End Date
March 6 2025
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Chulalongkorn Memorial Hospital
Bangkok, Thailand